Inhibrx Biosciences, Inc. Common Stock (INBX)
Inhibrx Biosciences, Inc. (INBX) is a biotech company focused on developing innovative therapies primarily in the areas of oncology, immunology, and rare diseases. Utilizing a proprietary protein discovery platform, Inhibrx designs targeted biologics and therapeutic candidates to address unmet medical needs. The company aims to advance its pipeline through preclinical and clinical development, emphasizing precision medicine approaches.
Company News
JMP Securities initiated coverage on Inhibrx Inc. with a Market Perform rating following the acquisition of INBRX-101 by Sanofi. The newly formed Inhibrx Biosciences has a strong financial foundation, but faces challenges with negative profitability metrics.
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -61.68% and 1,534%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Historically, consumer sentiment doesn't usually pick up while the business outlook is gloomy, except coming out of recessions.
Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Inhibrx The Trade: Inhibrx, Inc. (NASDAQ: INBX) Sharon Rose Shabet acquired a total of 511,627 shares an average price ...